Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating standard-of-care chemotherapy plus bevacizumab with or without INCA33890 as first-line treatment for metastatic microsatellite-sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• INCA33890

Snippet

Sponsor: Incyte Corporation | Conditions: CRC (Colorectal Cancer) | Phase 3 | Status: RECRUITING